M. Roy
Queen's University
6 Papers
235 Citations
M. Roy is an academic researcher from Queen's University. The author has contributed to research in topics: Carboplatin & Population. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
K Swenerton,J.F. Jeffrey,Gavin Stuart,M. Roy,Garry V. Krepart,J A Carmichael,P Drouin,R Stanimir,G O'Connell,Gd Maclean +9 more
TL;DR: It may be inappropriate to expect that any single regimen can be an effective therapy for all patients with advanced ovarian cancer, and both cisplatin and carboplatin are likely to have a role in future treatment strategies.
222
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.
P Hoskins,Eric L. Eisenhauer,S Beare,M. Roy,P Drouin,Gavin Stuart,Peter Bryson,R. Grimshaw,V Capstick,Benny Zee +9 more
TL;DR: The weekly 24 hour infusion of topotecan at 1.75 mg/m2 was ineffective in relapsed ovarian cancer, and the daily-times-five schedule remains the schedule of choice.
171
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
Andres Poveda,Ignace Vergote,Sergei Tjulandin,B. Kong,M. Roy,Stephen Chan,E. Filipczyk-Cisarz,Hans Hagberg,Stan B. Kaye,Nicoletta Colombo,C. Lebedinsky,Trilok V. Parekh,J. Gomez,Youn C. Park,V. Alfaro,Bradley J. Monk +15 more
TL;DR: This hypothesis-generating analysis demonstrates that superior benefits with trabectedin/PLD in terms of PFS and survival in the overall population appear particularly enhanced in patients with partially sensitive disease (PFI 6–12 months).
165
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
Stan B. Kaye,Nicoletta Colombo,Bradley J. Monk,Sergei Tjulandin,B. Kong,M. Roy,Stephen Chan,E. Filipczyk-Cisarz,Hans Hagberg,Ignace Vergote,C. Lebedinsky,Trilok V. Parekh,P. Santabarbara,Youn C. Park,Antonio Nieto,Andres Poveda +15 more
TL;DR: Analysis of subsequent therapies and survival outcomes in the overall population and in the subsets according to platinum sensitivity support the hypothesis that the enhanced survival benefits in the partially platinum-sensitive subset might be due to an extended PFI leading to longer survival with subsequent platinum.
62
Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study.
Andres Poveda,Sergei Tjulandin,B. Kong,M. Roy,Stephen Chan,E. Filipczyk-Cisarz,Hans Hagberg,C. Lebedinsky,Trilok V. Parekh,Bradley J. Monk +9 more
TL;DR: Baseline characteristics of pts with PPS were balanced and consistent with those of the overall study population, and outcomes of this nonplatinum combination on PFS, RR and OS are shown.
11